Olema Pharmaceuticals, Inc. financial data

Symbol
OLMA on Nasdaq
Location
780 Brannan Street, San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.08K % +15.7%
Debt-to-equity 10.4 % -12.9%
Return On Equity -41.5 % +22.5%
Return On Assets -37.6 % +21.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68.7M shares +19.8%
Common Stock, Shares, Outstanding 68.7M shares +19.8%
Entity Public Float 454M USD +85.3%
Common Stock, Value, Issued 7K USD +75%
Weighted Average Number of Shares Outstanding, Basic 85.7M shares +49.7%
Weighted Average Number of Shares Outstanding, Diluted 85.7M shares +49.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 147M USD +24.3%
General and Administrative Expense 18.6M USD +4.43%
Operating Income (Loss) -165M USD -21.7%
Nonoperating Income (Expense) 15.4M USD +16.6%
Net Income (Loss) Attributable to Parent -150M USD -22.2%
Earnings Per Share, Basic -1 USD/shares +14.3%
Earnings Per Share, Diluted -1 USD/shares +14.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.3M USD -1.75%
Marketable Securities, Current 294M USD +64.2%
Cash, Cash Equivalents, and Short-term Investments 329M USD +53.2%
Assets, Current 334M USD +53.4%
Property, Plant and Equipment, Net 486K USD -42.8%
Operating Lease, Right-of-Use Asset 1.42M USD -9.45%
Other Assets, Noncurrent 15K USD -6.25%
Assets 352M USD +53.1%
Accounts Payable, Current 3.47M USD +29.4%
Employee-related Liabilities, Current 406K USD -67.2%
Liabilities, Current 41.7M USD +35.7%
Operating Lease, Liability, Noncurrent 310K USD -44.8%
Liabilities 45M USD +43.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 526K USD +13.4%
Retained Earnings (Accumulated Deficit) -551M USD -37.3%
Stockholders' Equity Attributable to Parent 307M USD +54.6%
Liabilities and Equity 352M USD +53.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -44M USD -87.2%
Net Cash Provided by (Used in) Financing Activities 222K USD -97.5%
Net Cash Provided by (Used in) Investing Activities -45.1M USD -124%
Common Stock, Shares Authorized 490M shares 0%
Common Stock, Shares, Issued 68.7M shares +19.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -88.8M USD -155%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.3M USD -1.75%
Deferred Tax Assets, Valuation Allowance 105M USD +46%
Deferred Tax Assets, Gross 105M USD +44.9%
Operating Lease, Liability 1.48M USD -13%
Payments to Acquire Property, Plant, and Equipment 153K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -150M USD -22.9%
Lessee, Operating Lease, Liability, to be Paid 1.55M USD -14.3%
Property, Plant and Equipment, Gross 1.75M USD -7.1%
Operating Lease, Liability, Current 1.17M USD +2.73%
Lessee, Operating Lease, Liability, to be Paid, Year Two 69K USD -73.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.17M USD -5.94%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 76K USD -33.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 263K USD -68%
Deferred Tax Assets, Operating Loss Carryforwards 60.6M USD +35.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 1.24M USD +10.6%
Additional Paid in Capital 858M USD +43.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 128K USD +45.5%
Share-based Payment Arrangement, Expense 19.6M USD -4.69%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%